Arrayit Signs on Docro to Help Ovarian Cancer Diagnostic Gain FDA Clearance | GenomeWeb

Arrayit said this week that it has appointed Docro to help with its plans to get regulatory approval of its OvaDx ovarian cancer diagnostic in the US.

The company did not specify what role Docro would have, but said in a statement that the Seymour, Conn.-based diagnostic oncology contract research organization has "steered" almost 100 in vitro diagnostic clinical trials through the US Food and Drug Administration in the past 12 years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.